Pilot study of PCNU and cranial radiation therapy in the treatment of patients with malignant gliomas

Lynn G Feun, M. Maor, D. J. Stewart, M. E. Leavens, Niramol Savaraj, G. P. Bodey

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A pilot study was performed administering PCNU with radiation therapy to treat patients with high-grade astrocytomas and to explore the toxic effects of this drug regimen. PCNU at an initial dose of 110 mg/m2 i.v. was administered to 14 patients within 4 weeks after completion of cranial irradiation. Courses were repeated every 6-8 weeks upon recovery from myelosuppression. Radiation therapy consisted of 5,000 rad to the whole brain followed by an additional 1,500 rad to the tumor site. Patients were followed by CT scan and neurologic examination. The median survival for the group was 80 weeks. Larger, randomized trials comparing PCNU to other nitrosoureas will be needed to assess its value as adjuvant therapy in patients with malignant gliomas. Myelosuppression, particularly, thrombocytopenia, was the main toxic effect in this study. Pulmonary infiltrates developed in 2 patients and was progressive and fatal in 1 patient after a total cumulative PCNU dose of 850 mg/m2. Hepatic dysfunction with hyperbilirubinemia also developed in 1 patient. PCNU can produce pulmonary and hepatic toxicity similar to that reported for other nitrosoureas. Regular monitoring of pulmonary and hepatic function tests should be performed during treatment with PCNU in future trials.

Original languageEnglish
Pages (from-to)389-392
Number of pages4
JournalOncology
Volume47
Issue number5
StatePublished - Jan 1 1990
Externally publishedYes

Fingerprint

Glioma
Radiotherapy
Poisons
Therapeutics
Liver
Cranial Irradiation
Lung
Hyperbilirubinemia
Respiratory Function Tests
Astrocytoma
Neurologic Examination
1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea
Thrombocytopenia
Survival
Brain
Pharmaceutical Preparations
Neoplasms

Keywords

  • glioma
  • PCNU
  • radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pilot study of PCNU and cranial radiation therapy in the treatment of patients with malignant gliomas. / Feun, Lynn G; Maor, M.; Stewart, D. J.; Leavens, M. E.; Savaraj, Niramol; Bodey, G. P.

In: Oncology, Vol. 47, No. 5, 01.01.1990, p. 389-392.

Research output: Contribution to journalArticle

Feun, LG, Maor, M, Stewart, DJ, Leavens, ME, Savaraj, N & Bodey, GP 1990, 'Pilot study of PCNU and cranial radiation therapy in the treatment of patients with malignant gliomas', Oncology, vol. 47, no. 5, pp. 389-392.
Feun, Lynn G ; Maor, M. ; Stewart, D. J. ; Leavens, M. E. ; Savaraj, Niramol ; Bodey, G. P. / Pilot study of PCNU and cranial radiation therapy in the treatment of patients with malignant gliomas. In: Oncology. 1990 ; Vol. 47, No. 5. pp. 389-392.
@article{85811fc4fe824827bdf52d0933604d6d,
title = "Pilot study of PCNU and cranial radiation therapy in the treatment of patients with malignant gliomas",
abstract = "A pilot study was performed administering PCNU with radiation therapy to treat patients with high-grade astrocytomas and to explore the toxic effects of this drug regimen. PCNU at an initial dose of 110 mg/m2 i.v. was administered to 14 patients within 4 weeks after completion of cranial irradiation. Courses were repeated every 6-8 weeks upon recovery from myelosuppression. Radiation therapy consisted of 5,000 rad to the whole brain followed by an additional 1,500 rad to the tumor site. Patients were followed by CT scan and neurologic examination. The median survival for the group was 80 weeks. Larger, randomized trials comparing PCNU to other nitrosoureas will be needed to assess its value as adjuvant therapy in patients with malignant gliomas. Myelosuppression, particularly, thrombocytopenia, was the main toxic effect in this study. Pulmonary infiltrates developed in 2 patients and was progressive and fatal in 1 patient after a total cumulative PCNU dose of 850 mg/m2. Hepatic dysfunction with hyperbilirubinemia also developed in 1 patient. PCNU can produce pulmonary and hepatic toxicity similar to that reported for other nitrosoureas. Regular monitoring of pulmonary and hepatic function tests should be performed during treatment with PCNU in future trials.",
keywords = "glioma, PCNU, radiation therapy",
author = "Feun, {Lynn G} and M. Maor and Stewart, {D. J.} and Leavens, {M. E.} and Niramol Savaraj and Bodey, {G. P.}",
year = "1990",
month = "1",
day = "1",
language = "English",
volume = "47",
pages = "389--392",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Pilot study of PCNU and cranial radiation therapy in the treatment of patients with malignant gliomas

AU - Feun, Lynn G

AU - Maor, M.

AU - Stewart, D. J.

AU - Leavens, M. E.

AU - Savaraj, Niramol

AU - Bodey, G. P.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - A pilot study was performed administering PCNU with radiation therapy to treat patients with high-grade astrocytomas and to explore the toxic effects of this drug regimen. PCNU at an initial dose of 110 mg/m2 i.v. was administered to 14 patients within 4 weeks after completion of cranial irradiation. Courses were repeated every 6-8 weeks upon recovery from myelosuppression. Radiation therapy consisted of 5,000 rad to the whole brain followed by an additional 1,500 rad to the tumor site. Patients were followed by CT scan and neurologic examination. The median survival for the group was 80 weeks. Larger, randomized trials comparing PCNU to other nitrosoureas will be needed to assess its value as adjuvant therapy in patients with malignant gliomas. Myelosuppression, particularly, thrombocytopenia, was the main toxic effect in this study. Pulmonary infiltrates developed in 2 patients and was progressive and fatal in 1 patient after a total cumulative PCNU dose of 850 mg/m2. Hepatic dysfunction with hyperbilirubinemia also developed in 1 patient. PCNU can produce pulmonary and hepatic toxicity similar to that reported for other nitrosoureas. Regular monitoring of pulmonary and hepatic function tests should be performed during treatment with PCNU in future trials.

AB - A pilot study was performed administering PCNU with radiation therapy to treat patients with high-grade astrocytomas and to explore the toxic effects of this drug regimen. PCNU at an initial dose of 110 mg/m2 i.v. was administered to 14 patients within 4 weeks after completion of cranial irradiation. Courses were repeated every 6-8 weeks upon recovery from myelosuppression. Radiation therapy consisted of 5,000 rad to the whole brain followed by an additional 1,500 rad to the tumor site. Patients were followed by CT scan and neurologic examination. The median survival for the group was 80 weeks. Larger, randomized trials comparing PCNU to other nitrosoureas will be needed to assess its value as adjuvant therapy in patients with malignant gliomas. Myelosuppression, particularly, thrombocytopenia, was the main toxic effect in this study. Pulmonary infiltrates developed in 2 patients and was progressive and fatal in 1 patient after a total cumulative PCNU dose of 850 mg/m2. Hepatic dysfunction with hyperbilirubinemia also developed in 1 patient. PCNU can produce pulmonary and hepatic toxicity similar to that reported for other nitrosoureas. Regular monitoring of pulmonary and hepatic function tests should be performed during treatment with PCNU in future trials.

KW - glioma

KW - PCNU

KW - radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0025004562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025004562&partnerID=8YFLogxK

M3 - Article

C2 - 2170890

AN - SCOPUS:0025004562

VL - 47

SP - 389

EP - 392

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5

ER -